Acute myeloid leukaemia - Thorium dioxide (Thorotrast) Factor
Last reviewed for CCPS 08 January 2007.
Preliminary questions [36771]
36772 [1] there is some evidence that thorium dioxide (Thorotrast) may be a factor in the development of the condition under consideration.
36773 [1] the veteran has received thorium dioxide (Thorotrast) at some time.
36774 — the veteran has established the causal connection between thorium dioxide (Thorotrast) and VEA service for the clinical onset of acute myeloid leukaemia.
36776 — the veteran has established the causal connection between thorium dioxide (Thorotrast) and eligible service for the clinical onset of acute myeloid leukaemia.
or
36775 — the veteran has established the causal connection between thorium dioxide (Thorotrast) and operational service for the clinical onset of acute myeloid leukaemia.
Clinical onset and operational service [36775]
36777 [2] the veteran received thorium dioxide (Thorotrast) at least one year before the clinical onset of the condition under consideration. 36779 — the veteran received thorium dioxide (Thorotrast) for an illness or injury which is identifiable. 36782 — the identified illness or injury, for which the veteran received thorium dioxide (Thorotrast), is causally related to operational service. [4] [5] Clinical onset and eligible service [36776] 36779 — the veteran received thorium dioxide (Thorotrast) for an illness or injury which is identifiable.
36783 — the identified illness or injury, for which the veteran received thorium dioxide (Thorotrast), is causally related to eligible service. [9] [5]
Links
[1] https://clik.dva.gov.au/ccpsb044rc
[2] clikpopup://CCPS/Received Thorotrast 1 year before onset of AML
[3] clikpopup://CCPS/reject36777No
[4] clikpopup://CCPS/reject36780No
[5] clikpopup://CCPS/reject36782,36783No
[6] clikpopup://CCPS/Received Thorotrast 2 years before onset of AML
[7] clikpopup://CCPS/reject36778No
[8] clikpopup://CCPS/reject36781No
[9] clikpopup://CCPS/reject36783No